Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
The reinvention of Baxter goes on. The company that in the early “noughties” was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
The end of the COVID-19 sales opportunity was clearly visible in Medtech Insight ’s latest annual listing of the top 100 global medtech players by revenues for 2023. Medtronic once again assumed prid